Cortical Dysplasia: Causes, Risk Factors, and Understanding the Condition
Cortical dysplasia (CD) is a congenital malformation of cortical development characterized by abnormal neuronal organization, lamination, and/or cytology. It is a leading cause of drug-resistant epilepsy.
Etiology: Multifactorial
- Genetic: Somatic mutations in mTOR pathway genes (MTOR, DEPDC5, NPRL2/3, AKT3, PIK3CA, TSC1/2) – focal cortical dysplasia (FCD) types IIa/IIb. Germline mutations in tubulinopathies (TUBA1A, TUBB2B), FLNA, DCX (lissencephaly spectrum).
- Prenatal insults: Intrauterine infection (CMV, Zika, toxoplasmosis), ischemia/stroke, teratogens (alcohol, valproate), metabolic disorders.
- Developmental disruption: Abnormal neuronal proliferation, migration, differentiation, or apoptosis (weeks 8–24 gestation critical).
- Vascular: Disrupted cortical angiogenesis → ischemic/hypoxic injury.
Classification (ILAE 2022)
- Type I (architectural): Abnormal lamination (Ia) or columnar organization (Ib) – mild cytology.
- Type II (cytological + architectural): Dysmorphic neurons (IIa) + balloon cells (IIb) – "Taylor-type balloon cells."
- Type III: CD + another principal lesion (hippocampal sclerosis, tumor, vascular malformation, early injury).
Clinical Presentation
- Epilepsy (often focal, drug-resistant) – typical onset childhood/adolescence.
- Focal cognitive deficits (language, memory, executive) depending on location.
- Motor deficits if motor cortex involved.
Diagnosis
- MRI: High-resolution 3T epilepsy protocol – FCD signs: cortical thickening, blurred gray-white junction, transmantle sign (Type IIb), hyperintensity on FLAIR.
- EEG: Focal epileptiform discharges.
- FDG-PET: Hypometabolism in dysplastic zone.
- Genetic testing: Panel for mTORopathies, tubulinopathies if bilateral/familial.
Treatment
- Antiseizure medications: Often polytherapy; limited efficacy in FCD II.
- Epilepsy surgery: Resection of dysplastic tissue – best chance for seizure freedom (60–80% for FCD II).
- Neuromodulation: VNS, RNS if not surgical candidate.
- mTOR inhibitors (everolimus/sirolimus): Emerging for mTOR-related CD (TSC, FCD IIb).
Multidisciplinary epilepsy center evaluation is essential for drug-resistant cases.
Genetic Disorders - Related Articles
- External Mutagens: Radiation, Chemicals, UV, Oxidants, Viruses, and Transposons
- Ornithine Carbamoyltransferase (OCT) Deficiency: Causes, Symptoms & Treatment
- Delayed Hemolytic Transfusion Reaction in Sickle Cell Disease: Causes & Symptoms
- Enlarged Prostate (Benign Prostatic Hyperplasia): Symptoms & Causes
- Understanding Karyotyping: Chromosome Identification & Analysis
- Supporting Parents of Babies with Down Syndrome: A Guide for Friends
- Understanding the Genetics of Sickle Cell Disease
